Abbie Celniker Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Abbie Celniker SESN stock SEC Form 4 insiders trading

Abbie has made over 2 trades of the Sesen Bio stock since 2016, according to the Form 4 filled with the SEC. Most recently Abbie sold 10,031 units of SESN stock worth $30,093 on 28 September 2016.

The largest trade Abbie's ever made was selling 10,031 units of Sesen Bio stock on 28 September 2016 worth over $30,093. On average, Abbie trades about 2,866 units every 13 days since 2016. As of 28 September 2016 Abbie still owns at least 409,915 units of Sesen Bio stock.

You can see the complete history of Abbie Celniker stock trades at the bottom of the page.

What's Abbie Celniker's mailing address?

Abbie's mailing address filed with the SEC is C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE, MA, 02142.

Insiders trading at Sesen Bio

Over the last 6 years, insiders at Sesen Bio have traded over $121,419 worth of Sesen Bio stock. The most active insiders traders include Thomas R Cannell, Monica Forbes, and Mark Sullivan. On average, Sesen Bio executives and independent directors trade stock every 1 days with the average trade being worth of $111,396. The most recent stock trade was executed by Mark Sullivan on 2 March 2023, trading 298,175 units of SESN stock currently worth $175,923.

What does Sesen Bio do?

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.

Sesen Bio executives and stock owners

Sesen Bio executives and other stock owners filed with the SEC include:

• Thomas Cannell,
  President, Chief Executive Officer, Director
• Mark Sullivan,
  General Counsel, Corporate Secretary
• Dr. Thomas R. Cannell,
  Pres, CEO & Director
• Monica Forbes,
  Chief Financial Officer, Treasurer
• Monica Forbes,
  CFO & Treasurer
• Dr. Glen C. MacDonald,
  Chief Technology Officer
• Jason Keyes,
  Independent Director
• Carrie Bourdow,
  Independent Director
• Jane Henderson,
  Independent Director
• Jay Duker,
  Independent Chairman of the Board
• Glen MacDonald,
  Chief Technology Officer
• Daniel Lynch,
  Independent Director
• John Knighton,
  VP & Chief Compliance Officer
• Dr. Gregory L. Verdine Ph.D.,
  Co-Founder
• Dr. David Brooks,
  Sr. VP of Clinical Devel.
• Julie Hoff,
  VP of HR
• Steve Barbera,
  VP of Market Access
• Mark R. Sullivan,
  Gen. Counsel & Corp. Sec.
• Erin Clark,
  VP of Corp. Strategy & Investor Relations
• Elly Ryu,
  Corp. Controller & Principal Accounting Officer
• Dr. Gregory L. Verdine,
  Co-Founder
• Minori Rosales,
  Chief Development Officer
• Leslie Dan,
  Director
• Paul G Chaney,
  Director
• Abbie Celniker,
  Director
• Stephen A Hurly,
  President and CEO
• Wendy L Dixon,
  Director
• Dennis Kim,
  Chief Medical Officer
• Richard F Fitzgerald,
  Chief Financial Officer
• Peter Honig,
  Director
• Michael A. S. Jewett,
  Director
• Kirstin Anderson,
  Principal Accounting Officer
• Elly Ryu,
  Principal Accounting Officer